NEWS CONTACT US CAREERS GET E-MAIL ALERTS SEARCH Home About Us Our Products Our Pipeline Immunotechnology Plasma & IVIG Medical Affairs Investors Cash Flow Overview Press Releases Company Info Analyst Coverage Events & Webcasts Financial Info Stock Info SEC Filings Governance HOME INVESTORS FINANCIAL INFORMATION CASH FLOW CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) 9 Months Ended Sep. 30, 2021 Sep. 30, 2020 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ (54,998,198) $ (56,340,774) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 3,977,786 2,709,783 Loss on disposal of fixed assets 80,479 12,478 Stock-based compensation 2,274,860 2,166,940 Amortization of debt discount 1,394,142 1,344,344 Amortization of license revenue (107,125) (107,125) Changes in operating assets and liabilities: Accounts receivable (7,155,331) (2,864,617) Inventories (32,587,272) (16,687,794) Prepaid expenses and other current assets (2,812,580) (1,252,828) Deposits and other assets (813,415) (74,335) Accounts payable 6,209,132 (1,194,820) Accrued expenses 5,526,220 2,617,472 Other current and non-current liabilities 107,552 (112,246) Net cash used in operating activities (78,903,750) (69,783,522) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment (9,835,404) (9,128,359) Proceeds from the sale of property and equipment 0 2,000 Net cash used in investing activities (9,835,404) (9,126,359) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock, net of offering expenses 67,315,677 99,343,207 Proceeds from the exercise of stock options 0 13,432 Taxes paid on vested Restricted Stock Units (61,598) 0 Proceeds from issuance of note payable 0 12,500,000 Payments on finance lease obligations (25,507) (23,848) Net cash provided by financing activities 67,228,572 111,832,791 Net (decrease) increase in cash and cash equivalents (21,510,582) 32,922,910 Cash and cash equivalents - beginning of period 55,921,152 26,752,135 Cash and cash equivalents - end of period $ 34,410,570 $ 59,675,045 Source PDF HTML 10-Q Filing ZIP XLS HTML XBRL PUBLISHED: NOVEMBER 10, 2021 About Us Our Products Our Pipeline Inmunotechnology Plasma & IVIG Medical Affairs Investors Privacy Policy Disclaimer Sitemap Contact Us Connect with Us Email Alerts RSS © Copyright 2021 ADMA Biologics, Inc. Ramsey, NJ Offices 201-478-5552 Boca Raton, FL Offices 561-989-5800 info@admabio.com 2020 INNOVATOR AWARD NAMED 2019 COMPANY OF THE YEAR